Adipogenic adenoviruses as a biomarker for disease

• US 7,442,511 B2
• Filed: 12/27/2006
• Issued: 10/28/2008
• Est. Priority Date: 12/27/2005
• Status: Expired due to Fees

• Current Assignee: Obetech LLC
• Original Assignee: Obetech LLC, Obetech Obesity Research
• Inventors: Atkinson, Richard L.
• Primary Examiner(s): SALIMI, ALI REZA
• Application Number:
  US11/616,799
• Publication Number:
  US 20070218081A1
• Time in Patent Office: 671 Days
• Field of Search: 435/6, 435/7.1
• US Class Current: 435/6.16
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/235 Adenoviridae
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 5/38 of the suprarenal hormones
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Q 1/701 Specific hybridization probes
• CPC Class Codes: G01N 2333/075 Adenoviridae
• CPC Class Codes: G01N 33/574 for cancer

Abstract

This invention relates to the relationship between infection with adipogenic adenoviruses, such as adenovirus-36 (Ad-36) and the etiologies of obesity and obesity-related cancers and other diseases. Additionally, the invention relates to assaying a subject for Ad-36 status and using Ad-36 status as a marker for the presence of cancer, to predict the future risk of developing cancers, such as breast or prostate cancer, and/or to predict the aggressiveness and prognosis of these cancers.

Claims

1. A method for predicting cancer aggressiveness in a subject having an abnormality compatible with a tumor, said method comprising the steps of:

obtaining a sample from the subject;

assaying the sample to determine whether the subject is infected with an adipogenic adenovirus; and

predicting a more aggressive form of cancer in a subject infected with an adipogenic relative to a subject not infected with an adipogenic adenovirus.

2. The method of claim 1, wherein said step of assaying the sample comprises the steps of:

screening for the presence of antibodies specific to the adipogenic adenovirus in the sample; and

determining the presence of antibodies specific to the adipogenic adenovirus in the sample.

3. The method of claim 1, wherein the adipogenic adenovirus is one or more adipogenic viruses selected from the group consisting of adenovirus type 5, adenovirus type 36, and adenovirus type 37.

4. The method of claim 1, wherein the cancer is selected from the group consisting of breast, prostate, uterus, ovary, colon, kidney, pancreas, and lung.

5. The method of claim 1, wherein the subject is a human.

6. The method of claim 1, wherein the subject is an animal.

7. The method of claim 2, wherein the antibodies in said determining step are specific to one or more peptide encoded by the nucleic acid sequences selected from the group consisting of SEQ ID NO.:

5, SEQ ID NO.;

6, and SEQ ID NO.;

7.

8. The method of claim 2, wherein said screening step is performed by using a method selected from the group consisting of serum neutralization assay and ELISA.

9. The method of claim 1, wherein the sample is selected from the group consisting of a biological sample, body fluid, a tissue sample, an organ sample, feces, blood, saliva, and any combination thereof.

10. The method of claim 1, wherein the more aggressive form of cancer in the subject infected with the adipogenic adenovirus relative to the subject not infected with the adipogenic adenovirus is selected from the group consisting of higher tumor grade, larger tumor volume, advancing clinical stage, increased Gleason'"'"'s score, and higher grade dysplasia.